Significant progress in new stem cell drugs: Multiple sclerosis is being studied, T-MSC stem cell new drug completed the first patient medication in the United States

Embryonic stem cells are stem cell lines extracted during the embryonic blastocyst stage and established in vitro.
They can be expanded in vitro indefinitely and have the potential to differentiate into almost all tissues and organs of the body
.

Due to its unlimited expansion and differentiation potential, embryonic stem cells can be produced in a standardized way like chemical drugs, avoiding the limited sources of traditional adult stem cells and inconsistent quality problems, and they have great medical application prospects

Embryonic stem cells are stem cell lines extracted during the embryonic blastocyst stage and established in vitro.

Emstein Biotechnology Co.
, Ltd.
recently announced that at the Shepherd Center in Georgia, USA, its Phase 1 clinical trial of the new T-MSC (Trophoblast-Mesenchymal Stem Cell) stem cell drug (IMS001) has been completed.
Patients with multiple sclerosis medication
.
This is the world's first clinical trial of using embryonic stem cell-derived cells for systemic administration in humans
.
Previously, embryonic stem cell technology was only used for experimental treatments of local nervous system and eye diseases
.
This breakthrough marks a higher stage in the development and application of embryonic stem cell technology
.

T-MSC is a special mesenchymal stem cell derived from embryonic stem cell differentiation.
Through Emstein's two-step cell differentiation patented technology, a single human embryonic stem cell is differentiated from a trophoblast cell intermediate (Trophoblast)
.
After complete animal safety and effectiveness verification, and large-scale production quality control research, T-MSC's new drug under development has obtained the world's first FDA clinically approved new human embryo-derived mesenchymal stem cell drug for multiple sclerosis Disease treatment
.
The FDA
T-MSC new stem cell drug under development is a kind of allogeneic shelf stem cell product that can be injected intravenously into patients
.
Emstein plans to conduct a dose-escalation, open-label study to evaluate single-dose intravenous injections for patients with relapsing-remitting, secondary or primary progressive multiple sclerosis who have failed previous disease modification treatments (DMTs) The safety, tolerability and exploratory efficacy of T-MSC in research new drugs
.
“The series of new T-MSC stem cell drugs under development by the company are based on our research results in the past 10 years,” said researcher Wang Xiaofang, Emstein’s chief technology officer and inventor of T-MSC technology.
“We are very happy to see clinical trials.
The smooth development is undoubtedly a very critical step
.
The clinical value of mesenchymal stem cells has been widely achieved in the industry.
It is agreed that from the results of previous animal experiments and preclinical trials, T-MSC stem cells have outstanding advantages in terms of consistency, effectiveness, and mass production, and they have natural pharmaceutical properties
.
This feature T-MSC itself in a variety of new drugs including multiple sclerosis, including immune widely used on critical diseases
.
" Consensus Immunity
Dr.
Jeffery Cohen, a world-renowned multiple sclerosis expert, director of the Department of Neurology at the Mellon Medical Center in Cleveland, USA, and a neurological disease stem cell therapy expert, gives great hope to T-MSC in the development of new drugs.
"As Emstein's scientific consultant, I am very excited to see the smooth development of this clinical trial.
We sincerely hope that we can find a drug that can effectively treat and even cure multiple sclerosis
.
" Leave a message here